FATE THERAPEUTICS INC Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO total compensation $2.25M; PEO compensation actually paid $1.65M; Other NEO average total compensation $913.40K.
- 2024-12-31: PEO total compensation $4.18M; PEO compensation actually paid $1.59M; Other NEO average total compensation $3.50M.
- 2023-12-31: PEO total compensation $3.52M; PEO compensation actually paid -$360.47K; Other NEO average total compensation $2.88M.
- 2024-12-31: PEO J. Scott Wolchko; PEO total compensation $4.18M; PEO compensation actually paid $1.59M; Other NEO average total compensation $3.50M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|
| 2025-12-31 | | $2.25M | $1.65M | $913.40K | $574.49K | $9.71 | | -$136.31M | | 2026-04-24 |
|---|
| 2024-12-31 | | $4.18M | $1.59M | $3.50M | $1.27M | $16.35 | | -$186.26M | | 2026-04-24 |
|---|
| 2023-12-31 | | $3.52M | -$360.47K | $2.88M | $617.78K | $37.07 | | -$160.93M | | 2026-04-24 |
|---|
| 2024-12-31 | J. Scott Wolchko | $4.18M | $1.59M | $3.50M | $1.27M | $2.82 | | -$186.26M | | 2025-04-17 |
|---|
| 2023-12-31 | | $3.52M | -$360.47K | $2.88M | $617.78K | $6.39 | | -$160.93M | | 2025-04-17 |
|---|
| 2022-12-31 | | $8.14M | -$12.37M | $3.18M | -$3.13M | $17.24 | | -$281.72M | | 2025-04-17 |
|---|
| 2023-12-31 | J. Scott Wolchko | $3.52M | -$360.47K | $2.88M | $617.78K | $4.11 | | -$160.93M | | 2024-04-26 |
|---|
| 2022-12-31 | | $8.14M | -$12.37M | $3.18M | -$3.13M | $11.10 | | -$281.72M | | 2024-04-26 |
|---|
| 2021-12-31 | | $11.73M | -$11.64M | $6.84M | -$2.08M | $64.35 | | -$212.15M | | 2024-04-26 |
|---|
| 2022-12-31 | J. Scott Wolchko | $8.14M | -$12.37M | $3.18M | -$3.13M | $51.56 | $111.27 | -$281.72M | | 2023-04-21 |
|---|
| 2021-12-31 | | $11.73M | -$11.64M | $6.84M | -$2.08M | $298.98 | $124.89 | -$212.15M | | 2023-04-21 |
|---|
| 2020-12-31 | | $5.60M | $78.60M | $3.27M | $22.80M | $46464.00 | $125.69 | -$173.39M | | 2023-04-21 |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
|---|
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
|---|